Clinical Trials Directory

Trials / Unknown

UnknownNCT05419739

Prognostic Value of Pediatric GCS-Pupil Score in Pediatric Patients With Traumatic Brain Injury

Status
Unknown
Phase
Study type
Observational
Enrollment
128 (estimated)
Sponsor
Uludag University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

There are studies reporting that the survival rate in pediatric patients with abnormal pupillary response is 23% and that pupillary response is effective on mortality and patient outcomes. Studies in the literature examining the effect of pupillary response on mortality and outcome in pediatric patients with traumatic brain injury reported that bilaterally dilated pupils were associated with a higher mortality rate. Considering the literature results, we believe that obtaining the GCS-Pupil score by combining GCS and pupillary reaction in pediatric patients with traumatic brain injury will be effective in predicting patient outcomes.

Detailed description

Obtaining a GCS-Pupil score using the total GCS score: 0 points are given for pupillary reaction if both pupils react to light, 1 point if one pupil does not react to light, and 2 points if both pupils do not react to light. Total GCS-P score is calculated by the formula of Eye Response + Verbal Response + Motor Response - Pupil Reaction and scores between 1-15. In the study, the worst GCS and current pupillary light reaction score in the first 24 hours will be evaluated.

Conditions

Interventions

TypeNameDescription
OTHERGlasgow coma scaleThis scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).

Timeline

Start date
2022-07-01
Primary completion
2023-07-01
Completion
2023-07-01
First posted
2022-06-15
Last updated
2022-06-22

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05419739. Inclusion in this directory is not an endorsement.